Disclaimer: This site analyses public FDA records. It is not medical advice. If you feel unwell, contact a healthcare professional immediately.
Supplement Safety Checker
Notice: Official Public Record

Noven Pharmaceuticals, Inc. FDA Warning (2018)

Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on April 21, 2018

MODERATE SEVERITY 2018
Disclaimer: This report is an analysis of a public FDA warning letter. It is not medical advice. If you have consumed these products and feel unwell, contact a healthcare professional immediately.

Executive Summary

The FDA issued a warning letter to Noven Pharmaceuticals, Inc. on April 21, 2018 citing regulatory violations. The letter was issued by the FDA.

Regulatory Violations

Detailed Analysis

False Claims and Regulatory Violations

The FDA identified regulatory violations in Noven Pharmaceuticals, Inc.'s operations or product claims.

Potential Health Risks

Mr. Jeff Mihm, President and CEONoven Pharmaceuticals Inc.11960 S.W. 144th StreetMiami, Florida 33186-6109

LCDR John W. Diehl, M.S.Director, Compliance BranchOffice of Pharmaceutical Quality Operations, Division II

Regulatory Context

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (FLA-16-21) dated August 5, 2016. Based on our evaluation during the January 18, 2018 through January 26, 2018 inspection of your firm, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have any questions regarding this letter, you may contact Jose R. Lopez atJoseR.Lopez@fda.hhs.govor by phone at(787) 729-8603. In addition, you may contact me at(214) 253-5288.

Key Entities Identified

Noven Pharmaceuticals Inc. FDA Warning Letter

Frequently Asked Questions

What did the FDA find wrong with Noven Pharmaceuticals, Inc.?
The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.
Are Noven Pharmaceuticals, Inc. products safe to use?
Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.
What should I do if I've used Noven Pharmaceuticals, Inc. products?
If you have used products from Noven Pharmaceuticals, Inc. and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.

Source Document

This report is based on an official FDA warning letter. The original document is a public record.

View Original FDA Warning Letter
Medical Disclaimer: This report is an analysis of public FDA warning letters. It is not medical advice. If you have consumed these products and feel unwell, contact a healthcare professional immediately. You can report adverse events to the FDA MedWatch program.